YL-13027

· Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for YL-13027, covering 2022-09-27 to 2025-12-08. Get the full timeline:

Most recent: Clinical Trial Update: A Trial of YL-13027 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Refractory Metastatic Pancreatic Cancer [Phase 1]

See pricing